A single injection of CJC-1295 raised growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9-11 days in healthy adults aged 21-61. The peptide's half-life was estimated at 5.8-8.1 days, and IGF-I stayed above baseline for up to 28 days after repeated dosing. No serious adverse reactions were reported, with 30-60 µg/kg doses best tolerated. But this 2006 trial measured hormones and safety, not muscle, fat or performance. Here is what the original data actually show, how CJC-1295 with DAC differs from mod GRF 1-29, and why the drug remains an unapproved, WADA-banned research peptide.
This page is available in
